Dabo Medical 2025 Annual Report: Net Profit Attributable to Parent Company Approximately RMB 600 Million, Overseas Revenue Up 44%

Source: Dabo Medical 2025 Annual Report

2025 Revenue: RMB 2.601 Billion (+21.79%) / Net Profit Attributable to Shareholders of the Parent Company: RMB 600 Million (+68.06%) / Overseas Business Revenue: RMB 312 Million (+43.81%)

DentalGoodNews｜On April 23, 2026, Dabo Medical Technology Co., Ltd. (hereinafter referred to as "Dabo Medical") released its 2025 annual report. The report shows that the company achieved operating revenue of RMB 2.601 billion in 2025, a year-on-year increase of 21.79%; Net Profit Attributable to Shareholders of the Parent Company was RMB 600 million, up 68.06% year-on-year. After deducting Non-recurring Gains and Losses, the company's Net Profit Attributable to Shareholders of the Parent Company for 2025 was RMB 480 million, a year-on-year increase of 68.06%. Total Non-recurring Gains and Losses amounted to approximately RMB 120 million, primarily composed of government subsidies and gains related to financial assets.

Source: Dabo Medical 2025 Annual Report

According to previous reports from DENTALGOODNEWS (Leading Dental Industry Media, DGN), Dabo Medical achieved operating revenue of RMB 1.876 billion in the first three quarters of 2025, with Net Profit Attributable to Shareholders of the Parent Company of RMB 425 million. Based on full-year data, the company achieved single-quarter revenue of RMB 725 million in the fourth quarter, with Net Profit Attributable to Shareholders of the Parent Company of RMB 175 million, and Net Profit Attributable to Shareholders of the Parent Company after deducting Non-recurring Gains and Losses of RMB 134 million.

Source: Dabo Medical 2025 Annual Report

By business segment, trauma products remained the core revenue source, achieving revenue of RMB 999 million, a year-on-year increase of 18.56%, accounting for 38.39% of total revenue. Dental products achieved revenue of RMB 71 million, a year-on-year increase of 8.04%, with the growth rate slowing compared to 28.25% in 2024, and the proportion of total revenue decreasing from 3.08% in 2024 to 2.73%.

Data shows that overseas business was a highlight of this reporting period. In 2025, the company's overseas business achieved revenue of RMB 312 million, a year-on-year increase of 43.81%, with its share of total revenue rising from 10.16% to 12.00%. The company's products have been exported to more than 70 countries and regions, including Australia, Ukraine, and Chile. The company stated that it will accelerate the international business process in the future to provide external growth momentum.

Source: Dabo Medical 2025 Annual Report

In terms of financial position, the company's net cash flow from operating activities was RMB 831 million, a year-on-year increase of 87.96%. As of the end of 2025, the company's total assets were RMB 4.924 billion, a year-on-year increase of 11.43%; net assets attributable to shareholders of the parent company were RMB 3.570 billion, a year-on-year increase of 15.95%.